A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).

Phase 1

• Conditions: Acute myeloid leukaemia (AML), Chronic myelomonocytic leukaemia (CMML) and Myelodysplastic syndrome (MDS); MedDRA version: 21.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 21.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 21.0Level: LLTClassification code 10054350Term: Chronic myelomonocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2020-000168-53-GB
• Lead Sponsor: Ellipses Pharma Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-06-03
• Last Update Posted: 10 August 2020

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 63

Inclusion Criteria

1. Male or female patients aged = 18 years of age, at the time of informed consent, with histological or cytological confirmation of an advanced malignancy
2. Ability to understand and provide written informed consent before any study-specific procedures, sampling, or analyses, including access to archival tumour tissue
3. Ability to swallow and retain oral medication
4. Sufficient life expectancy to allow the patient to complete at least 1 cycle (28 days) of the treatment period.
5. ECOG Performance Status of 0, 1 or 2 at Screening
6. In the opinion of the investigator, all other relevant medical conditions must be well-managed and stable for at least 28 days prior to first administration of study drug

Part A (escalation phase) only:
7. Patients with pathologically confirmed/documented AML or MDS, as defined by the 2017 European LeukaemiaNet (ELN) recommendations, or CMML, as defined by World Health Organization (WHO) criteria, who have relapsed from or are refractory to previous therapy.

Part B (Expansion cohort patients) only:
8. Patients with pathologically confirmed/documented AML, as defined by the 2017 European LeukaemiaNet (ELN) recommendations, who either decline or are unsuitable for standard therapy, or who are refractory to, or have relapsed after, initial treatment, with no more than 3 prior lines of therapy

Contraception (See Section 6.6)
9. Female patients should either be of non-child-bearing potential or must agree to use highly effective methods of contraception from Screening until 6 months following administration of the last dose of study drug
10. Male patients must use double barrier contraception from enrolment through treatment and for 6 months following administration of the last dose of study drug
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 43

Exclusion Criteria

Disease Under Study and Prior Anticancer Treatment
1. Suspected brain and/or leptomeningeal metastases that are symptomatic or untreated or that require current therapy
2. Acute promyelocytic leukaemia (FAB:M3)
3. Systemic anti-cancer therapy for the disease under study within 4 weeks of the first dose of study treatment. (Concomitant hydroxyurea is acceptable and will be permitted throughout the screening period and during first 2 cycles of study treatment)
4. Ongoing toxic manifestations of previous treatments that have not reduced to at least CTCAE Grade 1. Exceptions to this are alopecia or certain Grade 2 treatment related toxicities, which in the opinion of the Investigator should not exclude the patient.
5. Transplantation (allogeneic or autologous) within last 90 days, or on active immunosuppressive therapy for graft versus host disease in last 2 weeks

Laboratory Parameters
6. Patient with any out-of-range laboratory values defined as shown below. Haematology evaluations must be performed =7 days from any blood or blood product transfusion and =14 days from any dose of hematologic growth factor.
• Serum creatinine > 1.5 x upper limit of normal (ULN) and/or creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 50 mL/min
7. Inadequate liver function as demonstrated by
• serum bilirubin =3 times the upper limits of normal range (ULN) or
• alanine aminotransferase (ALT) =3 times the ULN or
• aspartate aminotransferase (AST) =3 times the ULN or
• AST or ALT =5 times the ULN in the presence of liver involvement by leukaemia

Medical History and Concomitant Medications
8. Confirmed QTcF > 470 msec on screening ECG or congenital long QT syndrome
9. Receiving an investigational anti-cancer treatment concurrently or within 14 days or five half-lives of either the parent drug or any active metabolite prior to the start of treatment with EP0042. Patients may receive hydroxyurea throughout the screening period and during the first 2 cycles of study treatment.
10. Any evidence of severe or uncontrolled systemic or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardize patient safety
11. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly affecting gastrointestinal (GI) function, re-section of the stomach, extensive small bowel re-section that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery such as gastric bypass.
12. Known history of human immunodeficiency virus infection (HIV) (testing is not required), ctive hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Testing for HBV or HCV status is not necessary unless clinically indicated or the patient has a history of HBV or HCV infection
13. Hypersensitivity to EP0042 or D -a-Tocopherol polyethylene glycol succinate (TPGS)
14. Malignant disease other than that being treated in this study, with the following exceptions:
• Malignancies that were treated curatively and have not recurred within 2 years prior to study treatment
• Completely resected basal cell and squamous cell skin cancers
• Any malignancy considered to be indolent and that has never required therapy
• Completely resected carcinoma in situ of any type
15. Any medical condition that would, in the investigator’s judgment, prevent

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified